HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Microplastic Will Test EU’s Green Tenacity As Cosmetics Regulatory Revision Looms

Executive Summary

Where the European Commission and Member States land in their final deliberations on the proposed microplastic ban could reveal a lot about industry costs deemed acceptable and the level of science considered necessary to regulate cosmetics and other markets in pursuance of Green Deal objectives.

You may also be interested in...



EU’s Planned Revision Of Cosmetics Regulation Makes For Uneasy Global Industry

To cosmetics industry stakeholders, the EU’s talk of instituting a generic risk management approach to eliminate “most hazardous” chemicals spells wholesale adoption of the precautionary principle, the disposal of exposure and risk considerations, and, ultimately, increased cosmetic ingredient restrictions and bans without proportionate human health benefits.

US FDA Says White Paper Could Inform Rulemaking For Cosmetic Talc-Asbestos Testing

Formed by the FDA in fall 2018 and convened in early 2020 for a public meeting, the Interagency Working Group on Asbestos in Consumer Products maintains that electron microscopy should be a first-line method for detecting asbestos in cosmetic talc and talc-containing products, and that labs should report elongate mineral particles beyond those classically understood as asbestos.

US FDA Advises Drug Firms To Test For Benzene Contamination As Root-Cause Investigation Continues

The FDA offers insight into possible sources of benzene contamination in drug products, including aerosol spray propellants, carbomers, or other drug components made from hydrocarbons. Manufacturers that find benzene in drug product batches at levels exceeding 2 ppm should not release the product or, if already in distribution, discuss with the FDA initiating a voluntary recall.

Topics

UsernamePublicRestriction

Register

RS151988

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel